V-016
烟酰胺 (维生素B3)标准液 CRM 溶液
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
别名:
烟酰胺, 维生素 B3, 吡啶-3-甲酰胺, 烟碱酰胺, 维生素 PP
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C6H6N2O
化学文摘社编号:
分子量:
122.12
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
200-659-6
Beilstein/REAXYS Number:
383619
MDL number:
grade
certified reference material
Quality Level
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
mp
128-131 °C (lit.)
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
SMILES string
NC(=O)c1cccnc1
InChI
1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
InChI key
DFPAKSUCGFBDDF-UHFFFAOYSA-N
General description
烟酰胺也称为烟碱酰胺或尼古丁酰胺。它是植物和动物食物中维生素B3的水溶性形式，并主要用作膳食补充剂。
Application
认证加标溶液适用于多种测试应用，包括通过 HPLC 对药物制剂或膳食补充剂进行的质量控制测试。
烟酰胺可作为分析参考标准品，用于通过经电喷雾质谱确证的平面色谱多重检测对功能饮料中的分析物、通过紫外-可见分光光度法和多元分析对药物制剂中的分析物进行测定。
烟酰胺可作为分析参考标准品，用于通过经电喷雾质谱确证的平面色谱多重检测对功能饮料中的分析物、通过紫外-可见分光光度法和多元分析对药物制剂中的分析物进行测定。
Biochem/physiol Actions
烟酰胺是维生素B3的酰胺衍生物，是PARP抑制剂
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Simultaneous determination of riboflavin, pyridoxine, nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry
Aranda M and Morlock G
Journal of Chromatography A, 1131(1-2), 253-260 (2006)
Simultaneous determination and classification of riboflavin, thiamine, nicotinamide and pyridoxine in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis
Lopez-de-Alba LP, et al.
Journal of the Brazilian Chemical Society, 17(4), 715-722 (2006)
Ning Jia et al.
Anticancer research, 33(6), 2797-2800 (2013-06-12)
Post-transplant hepatocellular carcinoma recurrence has been reported to be between 15-18% and is higher among patients with high-risk features (bilobar tumor, macrovascular invasion, or multifocality). There are no known treatments which reduce risk of recurrence post-transplant. Sorafenib is currently approved
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| V-016-1ML | 04061837428562 |